Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

Inclusion Criteria:

- Histologically or cytologically proven carcinoma of the pancreas that is locally
advanced

- ECOG performance status 0- 2

- Adequate labs

- No prior abdominal radiation therapy

- No other concurrent clinically evident malignancy, except inactive nonmelanoma skin
cancer, inactive cervical cancer, or other cancer for which the patient has been
disease-free for 5 years

- All disease must be encompassed within a radiotherapy portal

- Not pregnant or nursing

Exclusion Criteria:

- Patient has metastatic disease on radiological staging

- systemic therapy.

- Patient has known active infection with HIV, hepatitis C or hepatitis B

- Patient has serious medical risk factors involving any of the major organ systems
such that the Investigator considers it unsafe for the patient to receive an
experimental research drug.

- Patient is deemed to be have obvious resectable disease at presentation

- Received any investigational agent within a month prior to enrollment.

- Neuroendocrine tumors of the pancreas